List of Excipients in Branded Drug FOSCAVIR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Clinigen Limited	FOSCAVIR	foscarnet sodium	76310-024	HYDROCHLORIC ACID
Clinigen Limited	FOSCAVIR	foscarnet sodium	76310-024	WATER

Foscavir Excipient Strategy and Commercial Opportunities

Last updated: September 1, 2026

Foscavir is foscarnet sodium, an intravenous pyrophosphate analogue used primarily for acyclovir-resistant mucocutaneous herpes simplex virus infections and cytomegalovirus retinitis in patients with AIDS. Its commercial constraints are driven less by active-ingredient exclusivity than by renal toxicity, high osmolality, administration complexity, electrolyte monitoring, and the need for reliable hospital supply.

The strongest commercial opportunities are preservative-free ready-to-use presentations, lower-volume concentrated products, compatible infusion systems, improved container-closure systems, and hospital-focused supply contracts. A conventional reformulation must preserve chemical stability, avoid precipitation with common diluents, maintain low particulate levels, and support controlled intravenous administration.

What is Foscavir and how is it administered?

Foscavir contains foscarnet sodium, the sodium salt of phosphonoformic acid. It inhibits viral DNA polymerase and HIV reverse transcriptase without requiring activation by viral kinases. The FDA-approved product is an intravenous solution with a nominal concentration of 24 mg/mL foscarnet sodium hexahydrate, equivalent to 180 micromoles/mL of foscarnet and approximately 240 micromoles/mL of sodium [1].

Attribute	Foscavir
Active ingredient	Foscarnet sodium
Dosage form	Sterile intravenous solution
Strength	24 mg/mL
Primary uses	Acyclovir-resistant HSV; CMV retinitis
Route	Intravenous infusion
Preservatives	None identified in the FDA labeling
Key safety issue	Nephrotoxicity
Key formulation issue	Very high osmolality
Regulatory category	Small-molecule prescription drug
Biosimilar pathway	Not applicable

Foscavir is administered through an infusion pump. The product can be administered through a central venous catheter without dilution in certain clinical settings. Peripheral administration generally requires dilution because the solution is highly hypertonic and can cause local irritation or phlebitis [1].

The labeled dosing regimen is weight-based and varies by indication, renal function, and whether treatment is induction or maintenance therapy. Patients require hydration and frequent monitoring of serum creatinine, calcium, magnesium, potassium, and phosphate. These clinical requirements create opportunities for integrated administration products and hospital protocols, but they also limit the addressable market.

What excipients are used in Foscavir?

Foscavir is a relatively simple formulation. The commercial product is an aqueous, preservative-free solution of foscarnet sodium in Water for Injection. The FDA label identifies the solution as having a pH of approximately 7.2 to 7.6 and high osmolality [1].

Existing excipient profile

Formulation element	Role	Commercial implication
Foscarnet sodium	Antiviral active ingredient	High ionic load and renal safety burden
Water for Injection	Vehicle	Requires sterile manufacturing and particulate control
pH adjustment system	Maintains near-neutral pH	Must avoid precipitation and degradation
No antimicrobial preservative	Supports intravenous use	Requires single-use handling and aseptic controls
Sodium counterion	Part of active salt	Contributes to sodium load and osmolality

The label does not indicate a conventional buffer system comparable to phosphate, citrate, or acetate-buffered injectable formulations. Any proposed excipient change would need to account for foscarnet's phosphonate chemistry, sodium content, ionic strength, pH-dependent solubility, and compatibility with infusion materials.

The existing formulation's simplicity is commercially useful. It reduces excipient-related regulatory complexity and avoids hypersensitivity or compatibility concerns linked to surfactants, preservatives, or complex co-solvent systems. The disadvantage is that the product remains highly concentrated in dissolved ions and requires special administration management.

What formulation patents could protect a Foscavir competitor?

A new foscarnet product is unlikely to obtain meaningful protection from the basic active ingredient formulation alone because foscarnet sodium and its antiviral use are long-established. Commercially relevant protection would more likely involve a narrow formulation, packaging, administration, or manufacturing claim.

Potential claim categories include:

1. Reduced-osmolality formulations. A formulation that lowers osmolality while maintaining therapeutic concentration could reduce peripheral-vein irritation and dilution requirements.

2. Stable concentrated formulations. A product with improved stability at a concentration above or below 24 mg/mL could support smaller infusion volumes or longer shelf life.

3. Ready-to-dilute presentations. A controlled-concentration product packaged for direct dilution into standard saline or dextrose bags could reduce pharmacy preparation steps.

4. Infusion-compatible systems. Claims could cover a validated foscarnet solution and tubing, pump cassette, connector, or infusion bag that minimizes adsorption, leachables, precipitation, or particulate generation.

5. Container-closure systems. Polymer bags, multilayer films, elastomeric closures, and overwraps could be protected when they provide measurable stability or extractables advantages.

6. pH-control systems. A narrowly defined pH range or buffer-free stabilization method could support a formulation patent if linked to unexpected stability or compatibility results.

7. Manufacturing processes. Patentable subject matter could include crystallization, control of foscarnet polymorph or hydrate state, sterile filtration, aseptic filling, or particulate reduction.

Patent strength would depend on demonstrated technical effects. A claim that merely substitutes one conventional excipient for another would face enablement, obviousness, and written-description challenges. Stronger protection would require comparative data showing a material improvement in stability, tolerability, preparation time, or container compatibility.

When does Foscavir lose exclusivity?

Foscavir's core active-ingredient and basic formulation exclusivity expired long ago. The product is not dependent on an active biologic exclusivity period, and biosimilar competition is irrelevant because foscarnet sodium is a synthetic small molecule.

Exclusivity issue	Assessment
Core compound patent	Historical rights are expired
Basic injectable formulation	Historical rights are expired or commercially weak
New formulation patents	Possible for a redesigned product
Orphan-drug exclusivity	No current strategic reliance identified
Pediatric exclusivity	No central commercial role identified
Biosimilar exclusivity	Not applicable
Generic pathway	ANDA or other applicable small-molecule pathway
Current differentiation	Supply, presentation, administration, and quality

The practical barrier to entry is therefore not a fundamental patent monopoly. It is the combination of a small hospital market, complex dosing, renal monitoring, sterile manufacturing, product liability, and potentially limited commercial return.

What is the Orange Book status of Foscavir?

Foscavir is listed as an FDA-approved prescription injectable product under NDA 020068. Orange Book analysis should focus on the current patent-listing status for the NDA and any approved supplemental applications rather than historical patents associated with foscarnet.

A generic applicant would normally evaluate an abbreviated new drug application pathway and determine whether any listed patents require a Paragraph IV certification. If no relevant unexpired patents are listed, the primary legal and regulatory issues become pharmaceutical equivalence, bioequivalence or alternative evidence, manufacturing compliance, and labeling alignment.

What does a Paragraph IV challenge mean for Foscavir?

A Paragraph IV certification would assert that a listed patent is invalid, unenforceable, or not infringed. For a legacy injectable such as Foscavir, a Paragraph IV strategy would be commercially rational only if an unexpired formulation, method-of-use, or packaging patent materially blocked approval.

If no blocking patent is listed, an applicant would have little reason to use Paragraph IV litigation as its principal entry strategy. The applicant would instead rely on a certification that applicable patents have expired or do not exist, subject to the Orange Book record at the time of filing [2].

What formulation strategy offers the best commercial opportunity?

The most attractive strategy is a ready-to-use or pharmacy-efficient product that reduces operational burden without changing the clinical dose.

Strategy 1: Ready-to-use infusion bags

A manufacturer could offer premixed 24 mg/mL foscarnet sodium in single-use infusion bags or containers designed for direct connection to an infusion pump. Benefits would include:

• Less pharmacy compounding
• Lower preparation-error risk
• Reduced occupational exposure
• Faster treatment initiation
• More predictable final concentration
• Better inventory control

The product would need robust container-closure compatibility data, low extractables and leachables, acceptable shipping stability, and validated in-use hold times.

Strategy 2: Lower-volume concentrated product

A more concentrated formulation could reduce fluid burden for patients receiving repeated induction doses. This opportunity is clinically relevant because foscarnet therapy is frequently constrained by renal function, hydration needs, and infusion logistics.

The principal risks are increased osmolality, local tolerability, crystallization, and potential need for central venous access. A higher-strength product would therefore require a clear administration protocol and may have a narrower clinical use case.

Strategy 3: Reduced-osmolality formulation

Reducing osmolality could support peripheral infusion and improve patient convenience. This is technically difficult because foscarnet sodium contributes substantially to the solution's ionic load. Potential approaches include:

• Lower active concentration with a smaller total dose volume strategy
• Alternative salt or counterion screening
• pH and ionic-strength optimization
• Controlled dilution systems
• Co-packaged diluent presentations

A formulation that materially lowers osmolality without compromising dose delivery would have stronger commercial differentiation than a simple excipient substitution.

Strategy 4: Co-packaged hydration system

Foscavir treatment already depends on hydration to reduce renal injury. A manufacturer could develop a co-packaged treatment system containing foscarnet and a compatible hydration fluid, with labeling that supports standardized administration.

The commercial value would be operational rather than purely pharmaceutical. The product would still require careful regulatory treatment because the hydration fluid, infusion sequence, and compatibility claims could affect labeling and combination-product analysis.

Strategy 5: Pharmacy compounding kit

A kit could include a concentrated foscarnet solution, validated diluent, transfer device, and administration instructions. This model could improve preparation consistency in hospitals that do not prefer a premixed bag.

The IP opportunity would likely center on the kit configuration, compatibility data, and preparation method. Patent protection would be narrower than for a novel pharmaceutical composition.

How does Foscavir compare with competing antiviral treatments?

Foscavir competes primarily with cidofovir and, in some settings, high-dose or alternative antiviral therapy. The treatment choice depends on viral susceptibility, organ function, route of administration, and clinical urgency.

Product	Active ingredient	Route	Main use context	Key limitation
Foscavir	Foscarnet sodium	IV	Acyclovir-resistant HSV; CMV retinitis	Nephrotoxicity, electrolyte disturbances, infusion burden
Vistide	Cidofovir	IV	CMV retinitis in AIDS	Severe nephrotoxicity and hydration/probenecid requirements
Ganciclovir/valganciclovir	Ganciclovir	IV/oral	CMV infections	Myelosuppression; resistance considerations
Acyclovir/valacyclovir	Acyclovir	IV/oral	HSV and varicella-zoster	Resistance in selected immunocompromised patients
Maribavir	Maribavir	Oral	Refractory or resistant CMV after transplant	Different indication profile and resistance considerations

Foscavir retains value where acyclovir resistance limits standard therapy and where an intravenous antiviral is required. Its commercial position is therefore specialized rather than volume-driven.

What manufacturing and IP barriers affect Foscavir competition?

Sterile injectable manufacturing is the principal operational barrier. A competitor needs:

• Validated aseptic processing
• Sterile filtration and filling controls
• Low-particulate performance
• Container-closure integrity
• Stability across storage and shipping conditions
• Compatibility with infusion devices
• Controls for microbial contamination
• Reliable supply of pharmaceutical-grade foscarnet sodium

The active ingredient itself may be available from qualified suppliers, but supply-chain qualification remains important because a small market may not support multiple redundant sources. A manufacturer also needs a pharmacovigilance system capable of monitoring renal events, electrolyte abnormalities, infusion-site reactions, and medication errors.

Geographic coverage is likely to differ by jurisdiction. The United States, European Union, Canada, Japan, and selected hospital markets may use different product names, regulatory pathways, reimbursement systems, and approved indications. A global strategy would require separate assessment of national marketing authorizations, reference-product requirements, patent registers, and tender rules.

Which companies are challenging Foscavir?

Foscavir competition is more likely to arise from specialty injectable manufacturers and hospital-supply companies than from large generic portfolios seeking high-volume products. Potential participants include manufacturers with capabilities in:

• Sterile oncology and anti-infective injectables
• Hospital pharmacy products
• Ready-to-use infusion bags
• Small-volume specialty injectables
• Contract manufacturing and development
• International tender supply

Publicly available information does not establish a broad, active Paragraph IV litigation campaign against Foscavir. Competitive entry should instead be monitored through FDA abbreviated application approvals, product-label changes, drug-shortage records, procurement contracts, and national regulatory databases.

What is the revenue exposure for Foscavir?

Foscavir revenue is exposed to a narrow patient population and episodic treatment demand. The product may generate disproportionate value during resistant viral infections, but utilization is constrained by toxicity and specialist prescribing.

Revenue drivers include:

• Incidence of acyclovir-resistant HSV
• CMV disease in immunocompromised patients
• Transplant and oncology treatment volumes
• Hospital formulary placement
• Product availability during shortages
• Pricing under institutional contracts
• Geographic access
• Duration of induction and maintenance therapy

A new entrant should not rely on broad antiviral volume. The strongest business case would combine premium supply reliability with measurable reductions in pharmacy preparation, infusion time, wastage, or administration risk.

How strong is the patent estate for Foscavir?

The core Foscavir patent estate is commercially weak because the active ingredient and basic intravenous use are legacy technology. A new entrant should assume that market protection must be created through a differentiated product rather than inherited from the reference product.

IP category	Strength for incumbent	Opportunity for entrant
Active ingredient	Low	Minimal
Basic aqueous solution	Low	Minimal
New concentration	Medium if technically differentiated	Moderate
Reduced-osmolality formulation	Potentially strong	High if supported by data
Infusion container	Medium	Moderate
Administration kit	Narrow to medium	Moderate
Manufacturing process	Medium	Moderate
Method of use	Limited unless clinically distinct	Selective
Trademark and brand	Commercially relevant	Secondary

Method-of-use patents could be considered for patient subgroups, renal-adjusted dosing, infusion protocols, or resistant-virus treatment algorithms. Such claims would face significant validity and infringement constraints if they closely track established clinical practice.

What generic launch scenarios exist for Foscavir?

Scenario 1: Standard injectable generic

A conventional 24 mg/mL solution could enter with limited differentiation. This approach may require the lowest development investment but would face small-market economics and potential price pressure.

Scenario 2: Authorized or specialty generic

A manufacturer could offer the same formulation under a specialty label with stronger hospital distribution and supply commitments. The advantage would be commercial execution rather than formulation IP.

Scenario 3: Ready-to-use bag

A premixed product could command a higher price if it reduces pharmacy labor and preparation risk. Hospital pharmacy economics would determine adoption.

Scenario 4: Reformulated product

A lower-osmolality or improved-stability product could support composition-of-matter or formulation patents and a differentiated regulatory strategy. Development costs and clinical bridging requirements would be higher.

Scenario 5: Regional tender entrant

A manufacturer could target countries where procurement is price-sensitive and hospital supply is fragmented. This model would prioritize manufacturing scale, regulatory registrations, and dependable distribution.

Key Takeaways

• Foscavir is foscarnet sodium, a legacy intravenous antiviral with no biosimilar risk.
• The commercial opportunity is concentrated in formulation, packaging, administration, and supply reliability.
• The current product is a preservative-free aqueous solution at 24 mg/mL with high osmolality.
• Reduced-osmolality, ready-to-use, and pharmacy-efficient presentations offer the clearest differentiation.
• Core active-ingredient exclusivity is not the principal barrier to entry.
• Paragraph IV activity appears less important than sterile manufacturing, regulatory approval, hospital procurement, and product availability.
• A conventional generic may be technically feasible but commercially unattractive without reliable institutional demand.
• Stronger patent protection would require unexpected stability, tolerability, compatibility, or administration benefits.

FAQs

Can Foscavir be reformulated as an oral drug?

An oral formulation would face major absorption, dose-delivery, and clinical-development challenges. The commercial opportunity is more credible in improved intravenous presentations than in an oral reformulation.

Is foscarnet sodium compatible with normal saline?

Foscavir labeling permits dilution in compatible intravenous fluids under specified conditions. Compatibility must be established for the specific concentration, container, tubing, storage period, and administration system before commercial labeling claims are made [1].

Does Foscavir require a preservative?

The marketed product is preservative-free. Maintaining a single-use, preservative-free presentation is consistent with intravenous safety and avoids preservative compatibility issues.

Could a new Foscavir formulation receive patent protection?

Yes. Protection could be available for a novel concentration, reduced-osmolality composition, container system, administration kit, or manufacturing process if the claims are novel, non-obvious, adequately enabled, and supported by comparative data.

Is Foscavir vulnerable to substitution by maribavir?

Maribavir can compete in selected refractory or resistant CMV settings, but it is not a direct substitute for every Foscavir use. Route, disease site, patient population, susceptibility profile, and treatment urgency determine substitution potential.

References

1. U.S. Food and Drug Administration. (2023). Foscavir (foscarnet sodium) injection prescribing information. FDA.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
3. National Library of Medicine. (2024). Foscavir: Foscarnet sodium injection. DailyMed.
4. U.S. Food and Drug Administration. (2024). Guidance for industry: ANDAs for certain highly purified synthetic drug substances. FDA.